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Abstract
Background: Muscarinic receptor mediated adverse effects, such as sedation and xerostomia, significantly
hinder the therapeutic usefulness of first generation antihistamines. Therefore, second and third generation
antihistamines which effectively antagonize the H1 receptor without significant affinity for muscarinic receptors
have been developed. However, both in vitro and in vivo experimentation indicates that the third generation
antihistamine, desloratadine, antagonizes muscarinic receptors. To fully examine the in vivo antimuscarinic efficacy
of desloratadine, two murine and two rat models were utilized. The murine models sought to determine the
efficacy of desloratadine to antagonize muscarinic agonist induced salivation, lacrimation, and tremor.
Desloratadine's effect on the cardiovascular system was explored in both rodent models.
Results: In the pithed rat, both desloratadine (1.0 mg/kg, i.v.) and the muscarinic M2 selective antagonist,
methoctramine (0.5 mg/kg, i.v.), inhibited negative inotropic (left ventricular dP/dt) effects caused by
oxotremorine, a nonselective muscarinic agonist (p < 0.05). Negative chronotropic effects caused by
oxotremorine were inhibited by desloratadine, methoctramine, and the muscarinic M3 selective antagonist, 4-
DAMP (1.0 mg/kg, i.v.). A late positive inotropic event observed after the initial decrease was inhibited by all three
test compounds with desloratadine and 4-DAMP being the most efficacious. In the conscious animal, inhibition of
baroreflex-mediated bradycardia was evaluated. Unlike atropine (0.5 mg/kg, i.v.), desloratadine did not alter this
bradycardia. The antimuscarinic action of desloratadine on salivation, lacrimation, and tremor was also explored.
In urethane-anesthetized (1.5 g/kg, i.p.) male ICR mice (25–35 g) desloratadine (1.0, 5.0 mg/kg) did not inhibit
oxotremorine-induced (0.5 mg/kg, s.c.) salivation, unlike atropine (0.5 mg/kg) and 4-DAMP (1.0 mg/kg). In
conscious mice, desloratadine failed to inhibit oxotremorine-induced (0.5 mg/kg, s.c.) salivation, lacrimation, and
tremor. However, desloratadine did inhibit oxotremorine-induced tremor in phenylephrine pretreated animals.
Conclusion: The presented data demonstrate that the third generation antihistamine, desloratadine, does not
significantly antagonize peripheral muscarinic receptors mediating salivation and lacrimation, therefore,
xerostomia and dry eyes should not be observed with therapeutic use of desloratadine. Our data also indicate
when administered to a patient with a compromised blood-brain barrier, desloratadine may cause sedation.
Patients with compromised cardiovascular systems should be closely monitored when administered desloratadine
based on our results that desloratadine has the ability to interfere with normal cardiovascular function mediated
by muscarinic receptors.
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Background
Antihistaminergic drugs are commonly classified into
three generations. First generation antihistamines, such as
diphenhydramine, effectively block the H1 receptor sub-
type but their use is limited due to significant central
(sedation) and peripheral (tachycardia, xerostomia)
antimuscarinic side effects. Second generation antihista-
mines, such as loratadine, retain a high selectivity for the
H1 receptor and have fewer centrally mediated side effects
than the first generation compounds because second gen-
eration compounds do not readily enter the central nerv-
ous system (CNS) [1]. However, two second generation
antihistamines, astemizole and terfenadine, cause prolon-
gation of the QT interval resulting in torsades de pointes.
This adverse effect prompted the removal of terfenadine
from the drug market [2]. The most recent, third genera-
tion compounds, include fexofenadine and desloratadine.
These compounds are active metabolites of the second
generation antihistamines, terfenadine and loratadine,
respectively, and generally retain or surpass the H1 recep-
tor selectivity of their parent compounds. For instance,
desloratadine displays a higher affinity for the H1 receptor
than does loratadine and antagonizes the human H1
receptor in a pseudoirreversible manner [3,4].
Questions remain concerning the potential for antimus-
carinic adverse effects with desloratadine since both in
vitro and in vivo experimentation indicates that deslorata-
dine has the ability to block muscarinic receptors.
Desloratadine demonstrated in vitro IC50 values of 48 nM
and 125 nM against cloned human M1 and M3 muscarinic
receptor subtypes, respectively [4]. In vivo muscarinic
receptor blockade has been demonstrated in that deslorat-
adine has been shown to inhibit pilocarpine induced sal-
ivation in mice and inhibit contractions of isolated rabbit
and guinea pig iris smooth muscle [5,6]. Therefore, these
data present the need to more definitively ascertain the
potential antimuscarinic activity of desloratadine, in vivo.
In the present study, several in vivo models were used to
further assess antimuscarinic activity of desloratadine as
well as the potential for penetration of the blood-brain
barrier.
Results
Oxotremorine-induced tremor
Intraperitoneal injection of oxotremorine (0.5 mg/kg)
induced tremor in conscious mice. The only dose of
desloratadine causing inhibition of oxotremorine-
induced tremor was 5.0 mg/kg (Figure 1). Desloratadine
(1.0, 0.1, and 0.01 mg/kg) did not significantly inhibit
generation of tremor. Unlike atropine sulfate (0.5 mg/kg),
atropine methyl nitrate (0.5 mg/kg) did not inhibit trem-
ors which confirms the central locus for oxotremorine-
induced tremors. Diphenhydramine (1.0 mg/kg) signifi-
cantly inhibited the generation of tremor by oxotremorine
as did administration of both 4-DAMP (1.0 mg/kg) and
methoctramine (0.5 mg/kg) prior to administration of
oxotremorine.
Oxotremorine-induced tremor with phenylephrine 
pretreatment
Pretreatment with the vasopressor agent, phenylephrine
(10 µg/kg; PE), functions to disrupt the blood-brain bar-
rier by inducing acute hypertension [7,8]. Blood-brain
barrier disruption resulted in significant inhibition of
oxotremorine-induced tremors by desloratadine (1.0 mg/
kg) compared to the 1% DMSO vehicle as reflected by
their respective total tremor scores (Figure 2). Pretreat-
ment with PE followed by administration of deslorata-
dine (1.0 mg/kg; i.p.) elicited an oxotremorine-induced
total tremor score of 2.0 ± 0.7 (mean ± SD) whereas PE
pretreatment followed by vehicle elicited an oxotremo-
rine-induced total tremor score of 5.2 ± 1.3 (mean ± SD).
Inhibition of oxotremorine-induced tremors Figure 1
Inhibition of oxotremorine-induced tremors. Mice 
were treated with a single i.p. injection of one of the test 
agents (atropine sulfate, AT; atropine methyl nitrate, AMN; 
diphenhydramine, DPH; methoctramine, MOT; 1,1-dimethyl-
4-diphenylacetoxypiperidinium iodide, 4-DAMP; deslorata-
dine, DL) and placed in individual shoebox cages for observa-
tion. Fifteen minutes later, each mouse received a single s.c. 
injection of oxotremorine sesquifumarate (0.5 mg/kg) at the 
nape of the neck. At 5, 10 and 15 minutes following the 
oxotremorine injection, mice were observed for severity of 
tremor and for the presence of salivation and lacrimation. 
The sum of the scores for the three time points for tremor is 
presented as Total Tremor Score. Numbers in parenthesis 
represent the number of animals in each group and asterisk 
denotes statistical significance (P < 0.05) vs. control.
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Oxotremorine-induced salivation and lacrimation
Administration of oxotremorine (0.5 mg/kg, i.p.) elicited
salivation in conscious and urethane-anesthetized mice.
In conscious mice, oxotremorine-induced salivation was
not significantly inhibited by pretreatment with deslorat-
adine (0.01, 0.1, 1.0, and 5.0 mg/kg) (Figure 3). However,
salivation was significantly inhibited by pretreatment
with atropine (0.5 mg/kg), atropine methyl nitrate (0.5
mg/kg), and 4-DAMP (1.0 mg/kg). Pretreatment with
methoctramine (0.5 mg/kg) and diphenhydramine (1.0
mg/kg) failed to inhibit oxotremorine-induced salivation.
Inhibition of oxotremorine-induced salivation in ure-
thane-anesthetized mice yielded results similar to those
obtained in conscious male ICR mice. Pretreatment with
desloratadine (1.0 mg/kg) failed to significantly inhibit
oxotremorine-induced salivation (Figure 4). As in the
conscious animal, pretreatment with atropine (0.5 mg/
kg) and 4-DAMP (1.0 mg/kg) significantly inhibited
oxotremorine-induced salivation. Also, administration of
diphenhydramine (1.0 mg/kg) and methoctramine (0.5
mg/kg) failed to significantly inhibit saliva production.
Desloratadine (0.01, 0.1, 1.0, and 5.0 mg/kg) pretreat-
ment had no significant effect on oxotremorine-induced
lacrimation in conscious mice (Figure 5). As with inhibi-
tion of salivation in the conscious animal, pretreatment
with atropine (0.5 mg/kg) and 4-DAMP (1.0 mg/kg) sig-
nificantly inhibited oxotremorine-induced lacrimation.
Pretreatment with either methoctramine (0.5 mg/kg) or
diphenhydramine (1.0 mg/kg) did not significantly
inhibit oxotremorine-induced lacrimation.
Inhibition of oxotremorine-induced tremors with phenyle- phrine pretreatment Figure 2
Inhibition of oxotremorine-induced tremors with 
phenylephrine pretreatment. Male ICR mice (30–35 g) 
were treated with a single i.p. injection of phenylephrine 
hydrochloride (10 mg/kg; 10 µL/g). Each mouse was then 
placed in an individual shoebox cage for observation. Five 
minutes after this, each mouse was given a second i.p. injec-
tion of either vehicle (control; 10 µL/g) or desloratadine 
(free base) at a dose of 1.0 mg/kg (DL). Fifteen minutes later, 
each mouse received a single s.c. injection of oxotremorine 
sesquifumarate (0.5 mg/kg) at the nape of the neck. At 5, 10 
and 15 minutes following the oxotremorine injection, mice 
were observed for severity of tremor and for the presence 
of salivation and lacrimation. The sum of the scores for the 
three time points is presented as Total Tremor Score. Num-
bers in parenthesis represent the number of animals in each 
group and asterisk denotes statistical significance (P < 0.05) 
vs. control.
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Inhibition of lacrimation during oxotremorine-induced  tremors Figure 3
Inhibition of lacrimation during oxotremorine-
induced tremors. Mice were treated with a single i.p. injec-
tion of one of the test agents (atropine sulfate, AT; atropine 
methyl nitrate, AMN; diphenhydramine, DPH; methoc-
tramine, MOT; 1,1-dimethyl-4-diphenylacetoxypiperidinium 
iodide, 4-DAMP; desloratadine, DL) and placed in individual 
shoebox cages for observation. Fifteen minutes later, each 
mouse received a single s.c. injection of oxotremorine ses-
quifumarate (0.5 mg/kg) at the nape of the neck. At 5, 10 and 
15 minutes following the oxotremorine injection, mice were 
observed for severity of tremor and for the presence of sali-
vation and lacrimation. The sum of the scores for the three 
time points for lacrimation is presented as Total Lacrimation 
Score. Numbers in parenthesis represent the number of ani-
mals in each group and asterisk denotes statistical significance 
(P < 0.05) vs. control.
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Oxotremorine-induced changes in left ventricular 
contractility
Intravenous injections of oxotremorine (0.00125-0.02
mg/kg) elicited biphasic inotropic responses. The initial
phase consisted of a dose-dependent decrease in dP/dt.
This decrease in inotropy began approximately 30–60 sec-
onds after the beginning of oxotremorine injection and
lasted for approximately 60 seconds. Both desloratadine
and methoctramine treatments effectively blocked the
negative inotropic effect (Figure 6). Administration of
desloratadine (1.0 mg/kg) significantly inhibited
oxotremorine-induced (0.00125, 0.0025, and 0.02 mg/
kg) decreases in dP/dt indicated by a shift in the dose-
response curve to the right. Also, administration of meth-
octramine (0.5 mg/kg) significantly inhibited oxotremo-
rine-induced (0.0025, 0.01, 0.02 mg/kg) decreases in dP/
dt indicated by a shift in the dose-response curve to the
right. After administration of test agents, an additional
dose of oxotremorine (0.04 mg/kg) was administered
causing percentage decreases in left ventricular (LV)
contractility of -14.2 ± 2.7, -38.3 ± 7.6, and -20.7 ± 1.5 for
desloratadine, 4-DAMP, and methoctramine treatments,
respectively (data not shown). Treatment with 4-DAMP
had little antagonistic effect on the negative inotropic
response to oxotremorine.
The second phase of the inotropic response to oxotremo-
rine consisted of a dose-dependent increase in dP/dt. This
increase immediately followed the initial decrease and
had a duration of 2–5 minutes. Both desloratadine and 4-
DAMP antagonized the oxotremorine-induced positive
inotropic effect (Figure 7). Administration of deslorata-
dine (1.0 mg/kg) significantly inhibited oxotremorine-
induced (0.01 and 0.005 mg/kg) increases in dP/dt indi-
cated by a shift in the dose-response curve to the right.
Inhibition of salivation during oxotremorine-induced tremors Figure 4
Inhibition of salivation during oxotremorine-induced 
tremors. Mice were treated with a single i.p. injection of 
one of the test agents (atropine sulfate, AT; atropine methyl 
nitrate, AMN; diphenhydramine, DPH; methoctramine, 
MOT; 1, 1-dimethyl-4-diphenylacetoxypiperidinium iodide, 4-
DAMP; desloratadine, DL) and placed in individual shoebox 
cages for observation. Fifteen minutes later, each mouse 
received a single s.c. injection of oxotremorine sesquifuma-
rate (0.5 mg/kg) at the nape of the neck. At 5, 10 and 15 min-
utes following the oxotremorine injection, mice were 
observed for severity of tremor and for the presence of sali-
vation and lacrimation. The sum of the scores for the three 
time points for salivation is presented as Total Salivation 
Score. Numbers in parenthesis represent the number of ani-
mals in each group and asterisk denotes statistical significance 
(P < 0.05) vs. control.
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Inhibition of oxotremorine-induced salivation Figure 5
Inhibition of oxotremorine-induced salivation. Mice 
were anesthetized with urethane (1.5 g/kg, i.p.; 1 g/ml). Each 
mouse was then treated with a single i.p. injection of one of 
the test agents (atropine sulfate, AT; diphenhydramine, DPH; 
methoctramine, MOT; 1,1-dimethyl-4-diphenylacetoxypipe-
ridinium iodide, 4-DAMP; desloratadine, DL). Each mouse 
was then placed prone and head-down on a plexiglass plate 
inclined at 10° and covered with a sheet of Whatman no. 3 
MM filter paper. Fifteen minutes after administration of the 
test agent, a 0.5 mg/kg dose of oxotremorine was adminis-
tered in a volume of 1 µl/g. Every five minutes for 30 min-
utes, each mouse was moved up the incline. Salivation 
production was measured immediately following the move at 
the end of each collection period by measurement of the cir-
cumference of the moist area of filter paper immediately 
beneath each mouse's mouth. The sum of the 6 collection 
periods is listed as Total Salivation Score. Numbers in paren-
thesis represent the number of animals in each group and 
asterisk denotes statistical significance (P < 0.05) vs. control.
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Also, administration of 4-DAMP (1.0 mg/kg) significantly
inhibited oxotremorine-induced (0.005, 0.01, and 0.02
mg/kg) increases in dP/dt indicated by a shift in the dose-
response curve to the right. In contrast to desloratadine
and 4-DAMP, methoctramine treatment (0.5 mg/kg)
resulted in a statistically significant (P < 0.05) increases in
dP/dt after oxotremorine (0.01 and 0.02 mg/kg) adminis-
tration compared to control values recorded prior to
methoctramine treatment. After administration of test
agents, an additional dose of oxotremorine (0.04 mg/kg)
was administered causing percentage increases in LV con-
tractility of 32.2 ± 7.1, 20.5 ± 5.4, and 52.9 ± 9.5 for
desloratadine, 4-DAMP, and methoctramine treatments,
respectively (data not shown).
Oxotremorine-induced bradycardia
Administration of oxotremorine caused a dose-dependent
decrease in heart rate. All three of the test agents antago-
nized this decrease as indicated by a shift in the dose-
response curve to the right (Figure 8). After administra-
tion of all three test agents, the negative chronotropic
effects of oxotremorine (0.005, 0.01, and 0.02 mg/kg)
were significantly inhibited. Treatment with desloratadine
(1.0 mg/kg) or 4-DAMP (1.0 mg/kg) also significantly
inhibited the negative chronotropic response to oxotrem-
orine (0.0025 mg/kg) while methoctramine (0.5 mg/kg)
treatment inhibited the response to oxotremorine
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Effect of desloratadine (DL), 4-DAMP, or methoctramine on  oxotremorine-induced decrease in left ventricular contractil- ity in the pithed rat Figure 6
Effect of desloratadine (DL), 4-DAMP, or methoc-
tramine on oxotremorine-induced decrease in left 
ventricular contractility in the pithed rat. Isoflurane-
anesthetized animals (n = 6) were pithed after insertion of 
femoral and carotid arterial catheters. The carotid catheter 
was advanced into the LV to enable recording of contractil-
ity, which was expressed as the change in pressure over the 
change in time (dP/dt). Anesthesia was then discontinued. 
Following administration of atenolol (1.0 mg/kg, i.v.), 
oxotremorine was administered in random (n = 3) or 
ascending (n = 3) order of doses. The third generation anti-
histamine, DL (1.0 mg/kg, i.v.), the muscarinic M3 receptor 
antagonist, 4-DAMP (1.0 mg/kg, i.v.), or the muscarinic M2 
receptor antagonist, methoctramine (0.5 mg/kg, i.v.), was 
then administered and the oxotremorine doses were 
repeated. No statistically significant differences were found 
between animals in which oxotremorine was given in random 
vs. ascending order of doses and both sets of data were 
pooled. Data are representative of the maximal percent fall 
in dP/dt compared to control following the administration of 
each dose of oxotremorine. The highest dose tested for 
oxotremorine (0.04 mg/kg, i.v.) could not be given prior to 
treatment with 4-DAMP. Statistical analysis was done using 
the paired t-test with P < 0.05 denoting a statistically signifi-
cant difference versus control as indicated by an asterisk.BMC Pharmacology 2005, 5:13 http://www.biomedcentral.com/1471-2210/5/13
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(0.00125 mg/kg). After administration of test agents, an
additional dose of oxotremorine (0.04 mg/kg) was
administered causing percentage decreases in heart rate of
-18.8 ± 3.5, -32.1 ± 7, and -19.7 ± 4.2 for desloratadine, 4-
DAMP, and methoctramine treatments, respectively (data
not shown).
Inhibition of baroreceptor reflex
The ability of desloratadine to significantly alter the
baroreceptor reflex was assessed in the conscious rat. Data
were expressed as the percent change from corresponding
control values of blood pressure and heart rate and
subsequently analyzed by linear regression. The mean
slope values were then analyzed for significant differences
(data not shown). Administration of desloratadine (1.0
mg/kg) prior to stimulation of the baroreceptor reflex
resulted in a slope value of -0.708 ± 0.03 (mean ± SE; n =
6) with the corresponding control slope value of -0.795 ±
0.03 (n = 6) which was not a statistically significant differ-
ence. Unlike desloratadine, administration of atropine
(0.5 mg/kg) prior to stimulation of the baroreceptor reflex
resulted in a slope value of -0.548 ± 0.03 (n = 6) with the
corresponding control slope value of -0.670 ± 0.02 (n = 6)
which was a statistically significant difference (P < 0.05).
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Effect of desloratadine (DL), 4-DAMP, or methoctramine on  oxotremorine-induced increase of left ventricular contractil- ity in the pithed rat Figure 7
Effect of desloratadine (DL), 4-DAMP, or methoc-
tramine on oxotremorine-induced increase of left 
ventricular contractility in the pithed rat. Isoflurane-
anesthetized animals (n = 6) were pithed after insertion of 
femoral and carotid arterial catheters. The carotid catheter 
was advanced into the LV to enable recording of contractil-
ity, which was expressed as the change in pressure over the 
change in time (dP/dt). Anesthesia was then discontinued. 
Following administration of atenolol (1.0 mg/kg, i.v.), 
oxotremorine was administered in random (n = 3) and 
ascending (n = 3) order of doses. The third generation anti-
histamine, DL (1.0 mg/kg, i.v.), the muscarinic M3 receptor 
antagonist, 4-DAMP (1.0 mg/kg, i.v.), or the muscarinic M2 
receptor antagonist, methoctramine (0.5 mg/kg, i.v.) was 
then administered and the oxotremorine doses were 
repeated. No statistically significant differences were found 
between animals in which oxotremorine was given in random 
vs. ascending order of doses and both sets of data were 
pooled. Data are representative of the maximal percent 
increase in left ventricular contractility compared to control 
following the administration of each dose of oxotremorine. 
The highest dose tested for oxotremorine (0.04 mg/kg, i.v.) 
could not be given prior to treatment with 4-DAMP. Statisti-
cal analysis was done using the paired t-test with P < 0.05 
denoting a statistically significant difference versus control as 
indicated by an asterisk.BMC Pharmacology 2005, 5:13 http://www.biomedcentral.com/1471-2210/5/13
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Discussion
The focus of the present experiments was to determine the
degree of antimuscarinic effects exerted by desloratadine
at M2 and M3 receptors, in vivo. The non-selective mus-
carinic receptor agonist, oxotremorine [9], was employed
as the challenge agent in the murine and rat models.
Relatively selective antagonists at the M2 and M3 receptors,
methoctramine [10,11] and 4-DAMP [12,13], respec-
tively, were used for comparison. Our results indicate the
third generation antihistaminergic agent, desloratadine,
possesses a significant degree of antimuscarinic activity,
primarily against cardiac M2 and M3 receptor subtypes,
using in vivo whole animal preparations. However, the
doses at which these activities are demonstrated exceed
those normally utilized for therapeutic antihistaminergic
effects. In addition, while penetration of the blood-brain
barrier by desloratadine is unlikely to occur at therapeutic
doses [14], evidence has been obtained suggesting pene-
tration can be achieved and result in significant central
antimuscarinic effects if the blood-brain barrier is com-
promised by administration of a vasopressor agent.
Oxotremorine-induced tremor, salivation, and lacrima-
tion in the mouse have been used by others to evaluate the
presence of antimuscarinic actions of drugs of interest
[13,15,16]. The elicitation of tremor by oxotremorine is
centrally mediated [17,18] and blockade of this response
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Effect of desloratadine (DL), 4-DAMP, or methoc-
tramine on oxotremorine-induced decrease of heart 
rate (HR) in the pithed rat. Isoflurane-anesthetized ani-
mals (n = 6) were pithed after insertion of femoral and 
carotid arterial catheters. The femoral catheter was inserted 
approximately four centimeters into the femoral artery to 
enable recording of heart rate. Anesthesia was then discon-
tinued. Following administration of atenolol (1.0 mg/kg, i.v.), 
oxotremorine was administered in random (n = 3) and 
ascending (n = 3) order of doses. The third generation anti-
histamine, DL (1.0 mg/kg, i.v.), the muscarinic M3 receptor 
antagonist, 4-DAMP (1.0 mg/kg, i.v.), or the muscarinic M2 
receptor antagonist, methoctramine (0.5 mg/kg, i.v.), was 
then administered and the oxotremorine doses were 
repeated. No statistically significant differences were found 
between animals in which oxotremorine was given in random 
vs. ascending order of doses and both sets of data were 
pooled. Data are representative of the maximal percent fall 
in heart rate compared to control following the administra-
tion of each dose of oxotremorine. The highest dose tested 
for oxotremorine (0.04 mg/kg, i.v.) could not be given prior 
to treatment with 4-DAMP. Statistical analysis was done 
using the paired t-test with P < 0.05 denoting a statistically 
significant difference versus control as indicated by an 
asterisk.BMC Pharmacology 2005, 5:13 http://www.biomedcentral.com/1471-2210/5/13
Page 8 of 12
(page number not for citation purposes)
gauges penetration of an antimuscarinic agent across the
blood-brain barrier. Thus, blockade of oxotremorine-
induced tremor is indirectly indicative of the potential for
an antimuscarinic agent to exert central actions, such as
sedation, following peripheral administration. In the
presence of an intact blood-brain barrier, desloratadine
did not exert significant blockade of oxotremorine-
induced tremor, except at the highest dose tested (5.0 mg/
kg) which caused roughly 30% reduction in tremor sever-
ity. In contrast, following treatment with the vasopressor
agent, phenylephrine, to open the blood-brain barrier, a
previously ineffective dose of desloratadine (1.0 mg/kg)
caused a 60% reduction in tremor severity. These data sug-
gest that while desloratadine is unlikely to exert central
antimuscarinic effects at therapeutic dosages (5.0 mg rec-
ommended dose) in normal adults, considerably greater
CNS penetration may occur when the blood-brain barrier
is compromised. The significance of this when deslorata-
dine is combined with a vasopressor decongestant or
when infection may compromise the blood-brain barrier
[19,20] remains for further study. The present results
showing blockade by pretreatment with either methoc-
tramine or 4-DAMP, indicate that oxotremorine-induced
tremor is mediated by both M2 and M3 receptors in the
mouse as has been previously demonstrated by others
[13,21].
Both oxotremorine-induced lacrimation [22] and saliva-
tion [23] have been shown to be mediated selectively
through the M3 receptor subtype, a mediation confirmed
by the present study. Thus, while methoctramine
pretreatment had no effect on either variable, 4-DAMP
pretreatment was capable of reducing both lacrimation
and salivation by 60–80% below control responses. In
direct contrast, desloratadine inhibited neither lacrima-
tion nor salivation at doses as high as 5 mg/kg.
The pithed, atenolol-treated rat provides a useful acute
model with which to examine antimuscarinic drug action
on the circulatory system in the absence of both basal and
phasic sympathetic nervous system influences. The
administration of oxotremorine, in this model elicits
dose-dependent bradycardia, and biphasic effects on car-
diac inotropy. Oxotremorine causes an initial decline in
contractility, as determined by ventricular dP/dt, followed
by a more prolonged positive inotropic phase. This bipha-
sic inotropic response to a muscarinic agonist has been
previously reported for acetylcholine, bethanechol, and
carbachol in a variety of experimental species [24-27].
The rat heart contains multiple muscarinic receptors,
including the M1 [28], M2 [21], and M3 [29] subtypes. Of
these, the M2 subtype predominates based on reverse-tran-
scriptase polymerase chain reaction (rt-PCR) data indicat-
ing the M2 subtype constitutes more than 90% of the total
muscarinic receptor mRNA, therefore, supporting its role
as the major mediator of muscarinic influence over the
functional state of the myocardium [30]. However, Krejci
and Tucek also demonstrated the presence of mRNA for
M1 and M3 subtypes, each constituting less than 1% and
3%, respectively, of the total muscarinic receptor mRNA
in the rat heart [30]. M2 receptor agonists elicit bradycar-
dia and a negative inotropic response through inhibition
of cardiac adenylyl cyclase and/or an increase in potas-
sium conductance via the muscarinic potassium channel
[31,32]. In contrast, effects mediated through the M1 and/
or M3 receptors may lead to increased contractile strength,
through enhanced activity of phospholipase C and subse-
quent downstream events leading to increased intracellu-
lar free calcium availability [29,33]. Wang et al. [34] have
recently reviewed the existence of multiple muscarinic
receptors in the mammalian myocardium and have
emphasized the presence of and physiological functions
exerted by M3 receptors. A lesser body of data supports
functional actions of the M1 subtype.
Desloratadine, at a dose of 1.0 mg/kg, effectively antago-
nized bradycardia and both negative and positive ino-
tropic responses elicited by oxotremorine. Assuming
adequate selectivity between cardiac muscarinic receptor
subtypes, our data suggest the ability of methoctramine to
blunt oxotremorine-induced negative inotropic event and
the ability of 4-DAMP to blunt oxotremorine-induced
positive inotropic event to be indicative of M2 and M3
receptor mediation of these phenomena, respectively. In
contrast, however, both methoctramine (0.5 mg/kg) and
4-DAMP (1.0 mg/kg) blunted oxotremorine-induced
bradycardia. Therefore, the possibility exists that
oxotremorine-induced bradycardia is mediated by both
M2 and M3 receptor subtypes.
The context in which the present results are taken is wor-
thy of discussion. Both in vitro receptor binding data [35-
37] and results from prior in vivo studies [5,6,37] demon-
strate a considerably greater affinity of desloratadine for
histaminergic than muscarinic receptors (for reviews see,
[38,39]). Desloratadine has been found to exhibit a peak
plasma concentration of approximately 28 ng/ml in
healthy volunteers following a therapeutic antihistaminic
dose of its parent compound, loratadine [35]. Single oral
doses of desloratadine of 5, 7.5, 10, and 20 mg yielded
peak plasma concentrations of 2.18, 3.03, 3.80, and 8.08
ng/L in human volunteers [36]. In mice, desloratadine
exhibits an ED50 of 0.15 mg/kg in reduction of histamine
induced paw edema [37]. Cardelus et al. [5] noted local
antimuscarinic effects following topical ocular adminis-
tration of 1–10 mg/ml of desloratadine. However, it is
unlikely that systemic concentrations of desloratadine
would rise to levels approaching those in the present
study following normal therapeutic dosages of deslorata-BMC Pharmacology 2005, 5:13 http://www.biomedcentral.com/1471-2210/5/13
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dine, a fact which has been emphasized by others [37].
Thus, the antimuscarinic actions of desloratadine
demonstrated in the present study would, most probably,
be of significance only in overdose situations.
Conclusion
Our findings indicate that, at doses greater than those rec-
ommended for antihistaminergic therapy, desloratadine
causes significant blockade of cardiac M2 and possibly car-
diac M3 receptors, in vivo. This was demonstrated by signif-
icant inhibition of oxotremorine-mediated positive and
negative inotropic events and bradycardia by deslorata-
dine in the pithed rat. In contrast, desloratadine does not
significantly antagonize the M3 receptor subtype responsi-
ble for salivation and lacrimation as demonstrated by the
compound's inability to inhibit oxotremorine-mediated
salivation and lacrimation in the conscious mouse and
lacrimation in the anesthetized mouse. Also, under nor-
mal physiological conditions, desloratadine does not
effectively cross the blood-brain barrier. However, upon
disruption of this barrier, desloratadine has the potential
for CNS penetration and muscarinic receptor blockade.
Methods
Drugs and solutions
Test agents included atropine sulfate, atropine methyl
nitrate, diphenhydramine hydrochloride, methoctramine
hydrochloride, 1,1-dimethyl-4-diphenylacetoxypiperid-
inium iodide (4-DAMP), and desloratadine. All were
reconstituted in 1% DMSO / PBS, aliquoted into separate
vials, and stored at -20°C until used. With the exception
of desloratadine and 4-DAMP, all test agent concentra-
tions were calculated using the salt weights. Atropine
sulfate, atropine methyl nitrate, diphenhydramine hydro-
chloride, DMSO, oxotremorine sesquifumarate, atenolol,
halothane, and urethane were all purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Other purchased
agents were isoflurane (Abbott Laboratories; North Chi-
cago, IL, USA), methoctramine hydrochloride (ICN Bio-
chemicals, Inc.; Aurora, OH, USA), and 4-DAMP (Tocris;
Ellisville, MO, USA). Desloratadine was provided by
Aventis Pharmaceuticals (Bridgewater, NJ, USA).
Animal experiments
Male Sprague Dawley rats (275–325 g) and male ICR mice
(25–35 g) were purchased from Harlan Sprague Dawley
and housed in plastic group shoebox cages in an AAALAC-
approved Laboratory Animal Facility. Animals were
housed under a twelve hour light-dark cycle with food and
water ad libitum. Food was withheld twelve hours prior to
experimentation or surgical procedures. All animal use
protocols were approved by the University of Mississippi
Medical Center Institutional Animal Care and Use
Committee.
Inhibition of oxotremorine-induced tremor, salivation, and 
lacrimation
A murine model was used to test the ability of deslorata-
dine to antagonize muscarinic actions induced by admin-
istration of the muscarinic agonist, oxotremorine [15]. On
the afternoon of an experiment, each mouse was weighed
and placed in a clear shoebox cage for observation 15
minutes prior to any drug administration. Test agents for
this experiment were vehicle, atropine sulfate (0.5 mg/
kg), atropine methyl nitrate (0.5 mg/kg),
diphenhydramine hydrochloride (1.0 mg/kg), methoc-
tramine hydrochloride (0.5 mg/kg), 4-DAMP (1.0 mg/
kg), and desloratadine (5.0, 1.0, 0.1, and 0.01 mg/kg).
Each mouse was given a single intraperitoneal (i.p.) injec-
tion in a volume of 1 µl/g of one of the test agents. Fifteen
minutes later, each mouse received a single subcutaneous
(s.c.) injection of oxotremorine sesquifumarate (0.5 mg/
kg), a non-selective muscarinic agonist, at the nape of the
neck. At 5, 10, and 15 minutes following oxotremorine
injection, each mouse was assessed for the degree of
tremor and for the presence or absence of salivation and
lacrimation. A modified five-point grading scale was used
to evaluate tremor: 0 = no observable tremor; 0.5 = limb
tremor observable when mouse is held by the tail with all
feet off the cage bottom for 15 seconds; 1 = intermittent
tremor, with bouts lasting from 3–5 seconds; 2 = intermit-
tent tremor, with bouts lasting more than 5 seconds; or
continuous, fine tremor noticeable on tail and ears; 3 =
severe, continuous, whole-body tremor. Salivation and
lacrimation were separately evaluated on a two-point
scale: 0 = no observable salivation/lacrimation; 1 = saliva-
tion/lacrimation present. All responses were assessed by
each of two observers with no knowledge of the pretreat-
ment given each mouse. The grade for each mouse reflects
the sum of the three consecutive observations as either
Total Tremor, Total Salivation, or Total Lacrimation Score.
Inhibition of oxotremorine-induced salivation
A second paradigm, using mice (25–35 g), anesthetized
with ethyl carbamate (urethane, 1.5 g/kg, i.p., 1 g/ml) was
used to independently evaluate putative M3  receptor
blockade inhibition of oxotremorine-induced salivation.
This was modified after similar methods described for use
in the rat by Lavy and Mulder [16]. All mice were denied
access to food, but not to water, for 16 hours prior to anes-
thetization. Test agents for this experiment were vehicle,
atropine sulfate (0.5 mg/kg), diphenhydramine hydro-
chloride (1.0 mg/kg), methoctramine hydrochloride (0.5
mg/kg), 4-DAMP (1.0 mg/kg; free base) and desloratadine
(1.0 mg/kg; free base). A single i.p. injection of one of the
test agents or vehicle was administered in a volume of 1.0
µl/g five minutes following injection of urethane. Each
mouse was then placed prone and head-down on a plex-
iglass plate inclined at 10° and covered with a sheet of
Whatman no. 3 MM filter paper. Fifteen minutes after testBMC Pharmacology 2005, 5:13 http://www.biomedcentral.com/1471-2210/5/13
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agent administration, a 0.5 mg/kg (i.p.) dose of oxotrem-
orine was given in a volume of 1.0 µl/g body weight. Each
mouse was moved up the incline every five minutes for
thirty minutes. Saliva production was quantitated at the
end of each five-minute collection period by measure-
ment of the circumference of the moist area of filter paper
immediately beneath each mouse's mouth. The sum of
values from the six collection periods was recorded as
Total Salivation Score (TSS).
Inhibition of oxotremorine-induced tremor with 
phenylephrine pretreatment
Mice (30–35 g) were treated with a single i.p. injection of
phenylephrine hydrochloride (10 µg/kg; 10 µL/g) to ele-
vate systemic blood pressure and open the blood-brain
barrier [7,8]. Each mouse was then placed in an individual
shoebox cage for observation. Five minutes after this, each
mouse was given a second i.p. injection of either vehicle
or desloratadine (free base) at a dose of 1.0 mg/kg. Fifteen
minutes later, each mouse received a single s.c. injection
of oxotremorine (0.5 mg/kg) at the nape of the neck. At 5,
10, and 15 minutes post oxotremorine injection, mice
were observed for severity of tremor. The sum of the scores
for the three time points is presented as Total Tremor
Score.
Inhibition of oxotremorine-induced changes in cardiac 
function
The influence of oxotremorine over cardiac function in a
pithed rat model was employed to evaluate muscarinic
receptor antagonistic properties of desloratadine [15].
Male rats (275–325 g) were acutely anesthetized with 2–
4% isoflurane in medical grade oxygen. Polyethylene
arterial (PE-50) and venous (PE-10) catheters and a tra-
cheal cannula (PE-240) were surgically implanted to per-
mit monitoring of arterial blood pressure and
chronotropy, i.v. drug administration, and maintenance
of respiration by means of a Harvard rodent respirator,
respectively. A catheter (PE-50) was passed via the right
carotid artery into the left cardiac ventricle for measure-
ment of left ventricular dP/dt as an index of inotropy.
Responses were obtained using either a Grass Model
7P20G differentiator and recorded on a Grass Model 7D
polygraph (Grass Instrument Co.; Quincy, MASS, USA) or
with PowerLab/16 SP data acquisition system using Chart
for Windows v4.0 recording software (ADInstruments;
Colorado Springs, CO, USA). Each rat was then pithed by
insertion of a blunt stainless steel rod, 2 millimeters in
diameter, through the orbit of the eye and passed through
the brain and spinal column, thus destroying the central
nervous system (CNS) from forebrain to the terminus of
the spinal cord. Atenolol (10 mg/kg, 1.0 ml/kg, i.v.) was
administered to obviate peripheral catecholamine-
induced increases in cardiac function. After a 15 minute
stabilization period, doses of oxotremorine (0.00125,
0.0025, 0.005, 0.01, 0.02, 0.1 mg/kg), were administered
randomly and flushed with 0.1 ml of heparinized 0.9%
saline. Subsequently, a single i.v. injection of one of three
test agents was administered over a two minute period.
The test agents were desloratadine (1.0 mg/kg, 1.0 ml/kg,
i.v.), the selective M3 muscarinic receptor antagonist, 4-
DAMP (1.0 mg/kg, 1.0 ml/kg, i.v.), or the selective M2
muscarinic receptor antagonist, methoctramine (0.5 mg/
kg, 1.0 ml/kg, i.v.). All doses of oxotremorine were then
repeated in the order they were given prior to
administration of the test compound. Maximal changes in
chronotropy and inotropy were measured with each injec-
tion. Values are expressed as percent of the control value
taken immediately before injection of each dose of
oxotremorine.
Inhibition of baroreceptor reflex
Rats (300–325 g) were used to determine the ability of
desloratadine to block the vagally-mediated bradycardic
component of the baroreceptor reflex. Catheters were
inserted into the femoral artery (PE-50) and femoral vein
(PE-10) and exteriorized between the animal's shoulders.
Animals were allowed to recover for a minimum of three
days. The experiment lasted two days per animal. Before
the baroreceptor reflex of each animal was measured, the
animal was allowed an acclimation period. The first day
consisted of control baroreceptor reflex measurement. On
the second day, either desloratadine (1.0 mg/kg, i.v.) or
atropine (0.5 mg/kg, i.v.) was given prior to baroreceptor
challenge. After an acclimation period, baroreceptor reflex
measurement was repeated. The baroreceptor reflex was
initiated by increasing doses of both phenylephrine and
sodium nitroprusside to increase or decrease blood
pressure, respectively. Dosing was discontinued when a
maximal change of 50 mmHg was achieved. Blood pres-
sure was recorded with Powerlab Data Acquisition system
via a transducer attached to the arterial line. The linear
regression feature in Origin 6.0 (OriginLab Corp.; North-
hampton, MA) analyzed data and the slopes compared
with SigmaStat 2.0 (Jandel Scientific Software; San Rafael,
CA).
Statistical analysis
Data obtained from the murine models of oxotremorine-
induced salivation, lacrimation, and tremor were ana-
lyzed using a one-way repeated measures ANOVA with a
Dunn's  post hoc test. Data obtained from animals pre-
treated with either phenylephrine or vehicle was analyzed
via the paired t-test. Inhibition of oxotremorine-induced
alterations in cardiac function before and after either
desloratadine, methoctramine, or 4-DAMP
administration was analyzed via the paired t-test with
changes in cardiac function at each dose of oxotremorine
being compared. In all statistical comparisons, P ≤ 0.05
was deemed statistically significant.BMC Pharmacology 2005, 5:13 http://www.biomedcentral.com/1471-2210/5/13
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